Skip to main content Back to Top
Advertisement

9/22/2021

Methylprednisolone Acetate Injection

Products Affected - Description

    • Depo-Medrol injection, Pfizer, 20 mg/mL, 5 mL multiple dose vial, 1 count, NDC 00009-0274-01
    • Depo-Medrol injection, Pfizer, 40 mg/mL, 1 mL single dose vial, 1 count, NDC 00009-3073-01
    • Depo-Medrol injection, Pfizer, 40 mg/mL, 1 mL single dose vial, 25 count, NDC 00009-3073-03
    • Depo-Medrol injection, Pfizer, 40 mg/mL, 10 mL multiple dose vial, 1 count, NDC 00009-0280-03
    • Depo-Medrol injection, Pfizer, 40 mg/mL, 10 mL multiple dose vial, 25 count, NDC 00009-0280-52
    • Depo-Medrol injection, Pfizer, 40 mg/mL, 5 mL multiple dose vial, 1 count, NDC 00009-0280-02
    • Depo-Medrol injection, Pfizer, 40 mg/mL, 5 mL multiple dose vial, 25 count, NDC 00009-0280-51
    • Depo-Medrol injection, Pfizer, 80 mg/mL, 1 mL single dose vial, 1 count, NDC 00009-3475-01
    • Depo-Medrol injection, Pfizer, 80 mg/mL, 1 mL single dose vial, 25 count, NDC 00009-3475-03
    • Depo-Medrol injection, Pfizer, 80 mg/mL, 5 mL multiple dose vial, 1 count, NDC 00009-0306-02
    • Depo-Medrol injection, Pfizer, 80 mg/mL, 5 mL multiple dose vial, 25 count, NDC 00009-0306-12
    • Methylprednisolone Acetate injection, Teva, 40 mg/mL, 1 mL single dose vial, 1 count, NDC 00703-0031-01
    • Methylprednisolone Acetate injection, Teva, 40 mg/mL, 1 mL single dose vial, 25 count, NDC 00703-0031-04
    • Methylprednisolone Acetate injection, Teva, 40 mg/mL, 10 mL multiple dose vial, 1 count, NDC 00703-0045-01
    • Methylprednisolone Acetate injection, Teva, 40 mg/mL, 5 mL multiple dose vial, 1 count, NDC 00703-0043-01
    • Methylprednisolone Acetate injection, Teva, 80 mg/mL, 1 mL single dose vial, 1 count, NDC 00703-0051-01
    • Methylprednisolone Acetate injection, Teva, 80 mg/mL, 1 mL single dose vial, 25 count, NDC 00703-0051-04
    • Methylprednisolone Acetate injection, Teva, 80 mg/mL, 5 mL multiple dose vial, 1 count, NDC 00703-0063-01

Reason for the Shortage

    • Amneal has methylprednisolone acetate available.[1]
    • Pfizer has Depo-Medrol on shortage due to increased demand.[2]
    • Teva did not provide a reason for the shortage.[3]

Available Products

    • Methylprednisolone Acetate injection, Amneal, 40 mg/mL, 1 mL single dose vial, 1 count, NDC 70121-1573-01
    • Methylprednisolone Acetate injection, Amneal, 40 mg/mL, 1 mL single dose vial, 25 count, NDC 70121-1573-05
    • Methylprednisolone Acetate injection, Amneal, 80 mg/mL, 1 mL single dose vial, 1 count, NDC 70121-1574-01
    • Methylprednisolone Acetate injection, Amneal, 80 mg/mL, 1 mL single dose vial, 25 count, NDC 70121-1574-05

Estimated Resupply Dates

    • Teva has all presentations of methylprednisolone acetate on back order and the company cannot estimate a release date.
    • Pfizer has Depo-Medrol 20 mg/mL 5 mL multiple-dose vials, 80 mg/mL 1 mL single-dose vials in 1 count and 25 count, and 80 mg/mL 5 mL multiple-dose vials in 1 count in limited availability. All other presentations are on back order and the company estimates a release date of June 2022.

Alternative Agents & Management

    • The table below lists possible alternatives for patients who receive injectable corticosteroid suspensions.
    Table 1. Alternative agents for disorders commonly treated injectable corticosteroid suspensions.4-5
    Intra-articular injections for disorders such as rheumatoid arthritis and bursitisBetamethasone acetate/betamethasone sodium phosphate
    Intralesional injectionsTriamcinolone acetonide
    <40 mg per treatment

    Methylprednisolone acetate
    20 to 40 mg per treatment for large lesions


References

    1. Amneal (personal communication). August 20, 2021.
    2. Pfizer (personal communication). August 20, September 17, 2021.
    3. Teva (personal communication). August 20, September 17, 2021.
    4. Lexicomp Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc; 2018.
    5. Dexamethasone sodium phosphate injection [package insert]. Lake Zurich, IL: Fresenius Kabi; 2021.

Updated

Updated September 22, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. Created August 20, 2021 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.